u/viktor_laurent

sponsor disclosure is on the about page in full

Which programme and which readout are you quoting?

do not assume reconstitution intuitions apply, there is nothing to reconstitute

evidence rules are strict here on purpose

Did the pharmacy check with the wholesaler, or is that a shelf observation?

Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.

Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

consistent conditions or you are logging noise

Where to look instead of asking, which will nearly always be faster.

nl_verzekering is right that the two countries are separate systems and the answers diverge.

Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.

Reconstituted or powder, and how long has it been in solution?

no clinical trial has established what these threads assert

Cosigning on the no-links rule. It is the only reason the pricing threads are trustworthy.

sponsor disclosure is on the about page in full

Which phase 2 arm are you quoting, and at what week?

stopping is a plan, not an event

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

say what you are actually asking, the vocabulary here is imprecise

How fast was the escalation? That is usually the variable that explains the reports.

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

A log is a record of what you did. It is not a protocol, and posting one as a schedule for other members is a different thing that this board does not do.

daily dosing, not weekly, so the exposure profile is different

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

Not convinced by that DEXA comparison.

Adding the free proxy — track a few lifts monthly. It costs nothing and it is longitudinal.

Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Which phase 2 arm are you quoting, and at what week?

Disagree with the framing. Regain is the documented outcome after discontinuation; calling it a personal failure is both wrong and corrosive.

Small fix — that is the New Zealand arrangement, and the question is about Australia.

Withdrawal studies across this class consistently show substantial regain after discontinuation, with appetite typically returning before weight changes. That is a description of the pharmacology of a chronic condition.

read the actual papers, they are more modest than the summaries

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

Disagree with daily weighing. You are logging fluid, and the emotional cost is real for very little information.

Personal importation provisions exist, are narrow, and carry conditions.

Adding the quickest step — ask the pharmacist to check the wholesaler.

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.

Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.